CIDeRplusGeneral Information:
| Id: | 488 |
| Diseases: |
Diabetes mellitus, type II
- [OMIM]
Insulin resistance |
| Rattus norvegicus | |
| male | |
| article | |
| Reference: | Ye JM et al.(2002) Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liver. Endocrinology 143: 4527-4535 [PMID: 12446579] |
Interaction Information:
| Comment | In untreated rats insulin sensitivity decreased by 46% over 3-6 h of elevated free fatty acids (FFA), whereas it remained normal but with a 50% increase in FFA clearance in Pioglitazone-treated rats. |
|
Formal Description Interaction-ID: 2300 |
decreases_activity of phenotype |
| Comment | Plasma adiponectin was increased 2-fold in Pioglitazone-treated rats and was negatively correlated with hepatic glucose output and liver long-chain acyl-coenzyme A. |
|
Formal Description Interaction-ID: 2301 |
|
| Drugbank entries | Show/Hide entries for Pioglitazone |
| Comment | Pioglitazone-induced muscle insulin sensitization was largely diminished after matching plasma free fatty acid (FFA) elevation, but insulin-stimulated protein kinase B phosphorylation was protected. |
|
Formal Description Interaction-ID: 2302 |
|
| Drugbank entries | Show/Hide entries for Pioglitazone or AKT1 |
| Comment | Thiazolidinediones can protect against lipid-induced insulin resistance with a significant component (mainly liver) of the protective effect not requiring lipid lowering. This may be related to chronic elevation of adiponectin by thiazolidinediones. |
|
Formal Description Interaction-ID: 2305 |
drug/chemical compound Thiazolidinedione affects_activity of disease Insulin resistance |
| Comment | Pioglitazone treatment reduced plasma levels of triglycerides, FFAs, leptin, and insulin by 23%, 21%, 44%, and 29%, respectively, but did not alter glucose concentration. There was a slight (17%) increase in muscle triglyceride content, whereas no differences were found in glycogen and other lipid metabolites in muscle or liver among the groups. |
|
Formal Description Interaction-ID: 2315 |
drug/chemical compound decreases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for Pioglitazone |
| Comment | Pioglitazone treatment reduced plasma levels of triglycerides, FFAs, leptin, and insulin by 23%, 21%, 44%, and 29%, respectively, but did not alter glucose concentration. There was a slight (17%) increase in muscle triglyceride content, whereas no differences were found in glycogen and other lipid metabolites in muscle or liver among the groups. |
|
Formal Description Interaction-ID: 2316 |
drug/chemical compound decreases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for Pioglitazone |
| Comment | Pioglitazone treatment reduced plasma levels of triglycerides, FFAs, leptin, and insulin by 23%, 21%, 44%, and 29%, respectively, but did not alter glucose concentration. There was a slight (17%) increase in muscle triglyceride content, whereas no differences were found in glycogen and other lipid metabolites in muscle or liver among the groups. |
|
Formal Description Interaction-ID: 2317 |
|
| Drugbank entries | Show/Hide entries for Pioglitazone |
| Comment | Pioglitazone treatment reduced plasma levels of triglycerides, FFAs, leptin, and insulin by 23%, 21%, 44%, and 29%, respectively, but did not alter glucose concentration. There was a slight (17%) increase in muscle triglyceride content, whereas no differences were found in glycogen and other lipid metabolites in muscle or liver among the groups. |
|
Formal Description Interaction-ID: 2318 |
|
| Drugbank entries | Show/Hide entries for Pioglitazone |
| Comment | Pioglitazone treatment reduced plasma levels of triglycerides, FFAs, leptin, and insulin by 23%, 21%, 44%, and 29%, respectively, but did not alter glucose concentration. There was a slight (17%) increase in muscle triglyceride content, whereas no differences were found in glycogen and other lipid metabolites in muscle or liver among the groups. |
|
Formal Description Interaction-ID: 2320 |
|
| Drugbank entries | Show/Hide entries for Pioglitazone |
| Comment | Pioglitazone treatment reduced plasma levels of triglycerides, FFAs, leptin, and insulin by 23%, 21%, 44%, and 29%, respectively, but did not alter glucose concentration. There was a slight (17%) increase in muscle triglyceride content, whereas no differences were found in glycogen and other lipid metabolites in muscle or liver among the groups. |
|
Formal Description Interaction-ID: 2321 |
drug/chemical compound increases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for Pioglitazone |
| Comment | Pioglitazone treatment reduced plasma levels of triglycerides, FFAs, leptin, and insulin by 23%, 21%, 44%, and 29%, respectively, but did not alter glucose concentration. There was a slight (17%) increase in muscle triglyceride content, whereas no differences were found in glycogen and other lipid metabolites in muscle or liver among the groups. |
|
Formal Description Interaction-ID: 2322 |
drug/chemical compound NOT affects_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for Pioglitazone |
| Comment | In untreated rats insulin sensitivity decreased by 46% over 3-6 h of elevated free fatty acids (FFA), whereas it remained normal but with a 50% increase in FFA clearance in Pioglitazone-treated rats. |
|
Formal Description Interaction-ID: 12754 |
|
| Drugbank entries | Show/Hide entries for Pioglitazone |
| Comment | Thiazolidinediones can protect against lipid-induced insulin resistance with a significant component (mainly liver) of the protective effect not requiring lipid lowering. This may be related to chronic elevation of adiponectin by thiazolidinediones. |
|
Formal Description Interaction-ID: 12757 |
|